Bill Text: IL HB5604 | 2015-2016 | 99th General Assembly | Engrossed


Bill Title: Amends the Illinois Insurance Code, the State Employees Group Insurance Act of 1971, the Counties Code, the Illinois Municipal Code, the School Code, the Health Maintenance Organization Act, the Limited Health Service Organization Act, and the Voluntary Health Services Plans Act. Provides that a group or individual policy of accident and health insurance or managed care plan amended, delivered, issued, or renewed after the effective date of the amendatory Act shall provide coverage for treatment of pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections and pediatric acute-onset neuropsychiatric syndrome, including, but not limited to, the use of intravenous immunoglobulin therapy. Effective immediately.

Spectrum: Moderate Partisan Bill (Democrat 14-2)

Status: (Engrossed - Dead) 2016-05-27 - Rule 3-9(a) / Re-referred to Assignments [HB5604 Detail]

Download: Illinois-2015-HB5604-Engrossed.html



HB5604 EngrossedLRB099 18291 EGJ 42663 b
1 AN ACT concerning regulation.
2 Be it enacted by the People of the State of Illinois,
3represented in the General Assembly:
4 Section 5. The Illinois Insurance Code is amended by adding
5Section 356z.24 as follows:
6 (215 ILCS 5/356z.24 new)
7 Sec. 356z.24. Coverage for treatment of pediatric
8autoimmune neuropsychiatric disorders associated with
9streptococcal infections and pediatric acute onset
10neuropsychiatric syndrome. A group or individual policy of
11accident and health insurance or managed care plan that is
12amended, delivered, issued, or renewed after the effective date
13of this amendatory Act of the 99th General Assembly shall
14offer, for an additional premium and subject to the insurer's
15standard of insurability, optional coverage for treatment of
16pediatric autoimmune neuropsychiatric disorders associated
17with streptococcal infections and pediatric acute-onset
18neuropsychiatric syndrome, including, but not limited to, the
19use of intravenous immunoglobulin therapy.
20 Section 99. Effective date. This Act takes effect upon
21becoming law.
feedback